001446274 000__ 03086cam\a2200541Ii\4500
001446274 001__ 1446274
001446274 003__ OCoLC
001446274 005__ 20230310003948.0
001446274 006__ m\\\\\o\\d\\\\\\\\
001446274 007__ cr\un\nnnunnun
001446274 008__ 220429s2022\\\\sz\a\\\\o\\\\\000\0\eng\d
001446274 019__ $$a1313384946$$a1313888251$$a1324244749$$a1354205823
001446274 020__ $$a9783030953348$$q(electronic bk.)
001446274 020__ $$a3030953343$$q(electronic bk.)
001446274 020__ $$z9783030953331
001446274 020__ $$z3030953335
001446274 0247_ $$a10.1007/978-3-030-95334-8$$2doi
001446274 035__ $$aSP(OCoLC)1313073411
001446274 040__ $$aYDX$$beng$$erda$$epn$$cYDX$$dGW5XE$$dEBLCP$$dOCLCF$$dUKAHL$$dVLB$$dOCLCQ$$dN$T$$dDCT
001446274 049__ $$aISEA
001446274 050_4 $$aRC392$$b.N68 2022eb
001446274 08204 $$a616.8/4912061$$223/eng/20220505
001446274 24500 $$aNovel synthetic drugs in migraine /$$cPaolo Martelletti, Lars Edvinsson, editors.
001446274 264_1 $$aCham :$$bSpringer,$$c[2022]
001446274 264_4 $$c©2022
001446274 300__ $$a1 online resource (ix, 109 pages : illustrations).
001446274 336__ $$atext$$btxt$$2rdacontent
001446274 337__ $$acomputer$$bc$$2rdamedia
001446274 338__ $$aonline resource$$bcr$$2rdacarrier
001446274 347__ $$atext file$$bPDF$$2rda
001446274 4901_ $$aHeadache
001446274 50500 $$tNovel Pharmacological Targets of Migraine: An Overview --$$tMolecular and Cellular Mechanisms of CGRP Antagonists --$$tAtogepant --$$tUbrogepant --$$tRimegepant --$$tZavegepant --$$tMolecular Mechanisms of 5-HT1F Receptor Agonists --$$tLasmiditan --$$tUpdate on old and current targets for antimigraine therapies.
001446274 506__ $$aAccess limited to authorized users.
001446274 520__ $$aPublished in the series Headache, endorsed by the European Headache Federation, this is the first book on the novel synthetic treatment of migraine with ditans (lasmiditan) and gepants (atogepant, ubrogepant, rimegepant, vazegepant). These drugs will provide additional options for people with migraine put at risk of side effects by other medications or with unsatisfactory response to previous drugs. There is now a sufficient amount of literature published to interest a wide multidisciplinary readership (general physicians, general neurologists, clinical psychologists, neurologists in training, and medical students) facing every day this burdensome disorder in their clinical practice. The book aims therefore at offering an overview of these new drugs for both acute and prophylactic treatments of migraine, covering studies on clinical evidence, tolerability, and the different stages of clinical development.
001446274 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed May 5, 2022).
001446274 650_0 $$aMigraine$$xTreatment.
001446274 650_0 $$aSynthetic drugs.
001446274 655_0 $$aElectronic books.
001446274 7001_ $$aMartelletti, Paolo,$$eeditor.
001446274 7001_ $$aEdvinsson, Lars,$$eeditor.
001446274 77608 $$iPrint version:$$z3030953335$$z9783030953331$$w(OCoLC)1290014732
001446274 830_0 $$aHeadache (Springer (Firm))
001446274 852__ $$bebk
001446274 85640 $$3Springer Nature$$uhttps://univsouthin.idm.oclc.org/login?url=https://link.springer.com/10.1007/978-3-030-95334-8$$zOnline Access$$91397441.1
001446274 909CO $$ooai:library.usi.edu:1446274$$pGLOBAL_SET
001446274 980__ $$aBIB
001446274 980__ $$aEBOOK
001446274 982__ $$aEbook
001446274 983__ $$aOnline
001446274 994__ $$a92$$bISE